Navigation Links
Genomma Lab Announces 2009 Earnings Guidance
Date:12/10/2008

MEXICO CITY, Dec. 10 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), a leading Mexican over-the-counter ("OTC") pharmaceuticals and personal care products company, announced today its 2009 earnings guidance. The Company expects to reach organic growth without considering acquisitions in the range of 21% - 22% in net sales and an EBITDA(I) margin in the range of 27% - 28%. These estimates are based on the organic growth of core products (products launched during and before 2007); the full year effect in sales of those products launched during 2008; the growth of Genomma Lab's international operations; as well as the Company's launch program of product line extensions and new brands in new categories and in those in which the Company already participates.

Genomma Lab expects to maintain its strategy of brand acquisitions and, on a timely basis, will inform the market on any completed transaction, as well as the corresponding change to the Company's earnings guidance. As of the close of the third quarter 2008, the Company had a cash balance and equivalents of Ps. 1,073 million that may be used partially or totally for potential brand acquisitions.

Genomma Lab will continue its efforts to increase its share in the Mexican personal care and over-the-counter markets. The value of such markets is approximately Ps. 75 billion(II) and Ps. 19 billion(III), respectively.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

Genomma Lab performed its Initial Public Offering in June 2008, through a combined offering (mainly primary) and is listed on the Mexican Stock Exchange under the ticker symbol "LAB" (Bloomberg: labb.mx).

    Web Site: www.genommalab.com

      (I) EBITDA is defined as Operating Income plus Depreciation and
          Amortization
     (II) Source:  Euromonitor (2006)
    (III) Source:  Datamonitor (2007)

    Investor Relations in Mexico City:
    Tel: +52 (55) 5081 0000 Ext. 4250
    E-mail: inversion@genommalab.com

    In New York:
    i-advize Corporate Communications, Inc.
    Tel: (212) 406-3692
    E-mail: genomma@i-advize.com

'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Internacional Acquires UNIGASTROZOL
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
4. WellPoint Announces Appointment of Andrew J. Lang as Senior Vice President of Application Development
5. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
6. Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage
7. Allscripts Announces Expiration of Offer to Purchase in Cash 3.50% Convertible Senior Debentures due 2024
8. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
9. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
10. American Lung Association Announces Support of Pickens Plan
11. MassMutual Announces LEED-EB Certification Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden ... innovative patient - centric payment system, to expand its focus on patient care ... patient financial experience. , “At Ogden Clinic, we are working to become ...
(Date:3/23/2017)... ... 23, 2017 , ... Vortex Biosciences, provider of circulating tumor ... circulating tumor cells using microfluidic western blotting” in Nature Communications on March 23rd. ... to capture CTCs and a microfluidic single-CTC resolution Western blot from ...
(Date:3/22/2017)... ... March 22, 2017 , ... Sam ... insurance assistance, financial planning, and related services to residents of the region, is ... awareness of threatened species and wild lands. , Endangered Species International is committed ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that identifying savings ... Healthcare facilities across the country are always forced to focus on costs ... across the country, an efficient and quick way to estimate savings potential within ...
(Date:3/22/2017)... ... 2017 , ... Influence Health, the healthcare industry’s ... enabled Children’s Hospital of The King’s Daughters (CHKD) to achieve a 4:1 return ... a digital marketing approach, the 206-bed pediatric teaching hospital in Norfolk, Virginia, partnered ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , March 23, 2017 ... 2021, a latest research report. The global vagus nerve ... shift of surgeons focus toward minimally invasive VNS procedures. ... limited to few developed countries having high standards of ... ...
(Date:3/22/2017)... de marzo de 2017   VWR ... soluciones de productos y servicios para clientes de ... adquirido EPL Archives, Inc., una organización de servicios ... todo el ciclo de vida de investigación de ... de archivo, almacenamiento de documentos y servicios complementarios. ...
(Date:3/22/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Respiratory ... around 10.9% over the next decade to reach approximately $38.27 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: